Back to All NewsFDA Approves Botox Cosmetic for Moderate to Severe Forehead Lines
Posted By American Med Spa Association, Wednesday, October 4, 2017
Share
The FDA approved Allergan plc's Botox Cosmetic for its third indication, the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adults. This approval makes the brand the first and only neurotoxin indicated for three facial treatment areas—forehead lines, crow's feet lines, and glabellar lines. Botox Cosmetic is the only neurotoxin brand to receive approval of aesthetic indications beyond glabellar lines in the US.
"Allergan recognizes that forehead lines are a top area of concern for patients," says David Nicholson, Chief Research and Development Officer at Allergan. "Our goal in pursuing a third indication for BO Cosmetic for the temporary improvement in the appearance of moderate to severe forehead lines was based on our desire to study the patient selection, dosing and injection pattern to help provide optimal treatment outcomes."
In 2002, Botox Cosmetic received its first FDA approval to temporarily improve the appearance of moderate to severe frown lines between the eyebrows (glabellar lines). The momentum continued in 2013 when Botox Cosmetic was approved for the temporary improvement in the appearance of moderate to severe crow's feet lines. The addition of this third indication furthers Allergan's mission to continue providing patients and physicians with products designed to address specific patient needs.
"As a physician, I've been using Botox Cosmetic since it was FDA approved in 2002, but for years my patients have also inquired about how to treat forehead lines. With this latest indication for Botox Cosmetic, I have an FDA-approved product I already know and trust, that can improve the appearance of the forehead," says Dr. Steven Fagien, an Oculoplastic Surgeon in Boca Raton, FL and lead clinical trial investigator. "I am proud to have worked closely with Allergan to establish criteria for proper patient selection, dosing and injection pattern for forehead line treatment and am pleased to see that the company is providing extensive injector training to help ensure optimal results."
Read more at Aesthetics Wire >>
"Allergan recognizes that forehead lines are a top area of concern for patients," says David Nicholson, Chief Research and Development Officer at Allergan. "Our goal in pursuing a third indication for BO Cosmetic for the temporary improvement in the appearance of moderate to severe forehead lines was based on our desire to study the patient selection, dosing and injection pattern to help provide optimal treatment outcomes."
In 2002, Botox Cosmetic received its first FDA approval to temporarily improve the appearance of moderate to severe frown lines between the eyebrows (glabellar lines). The momentum continued in 2013 when Botox Cosmetic was approved for the temporary improvement in the appearance of moderate to severe crow's feet lines. The addition of this third indication furthers Allergan's mission to continue providing patients and physicians with products designed to address specific patient needs.
"As a physician, I've been using Botox Cosmetic since it was FDA approved in 2002, but for years my patients have also inquired about how to treat forehead lines. With this latest indication for Botox Cosmetic, I have an FDA-approved product I already know and trust, that can improve the appearance of the forehead," says Dr. Steven Fagien, an Oculoplastic Surgeon in Boca Raton, FL and lead clinical trial investigator. "I am proud to have worked closely with Allergan to establish criteria for proper patient selection, dosing and injection pattern for forehead line treatment and am pleased to see that the company is providing extensive injector training to help ensure optimal results."
Read more at Aesthetics Wire >>
